MEDFORD, Mass., September 10, 2012 — Agrivida, Inc., a developer of biotechnologies for agricultural and industrial processing, announced today that it has raised $15 million as part of a Series C financing to advance the development and commercialization of its proprietary technologies. Bright Capital led the round.  Other Series C investors include Kleiner Perkins Caufield & Byers, DAG Ventures, Prairie Gold, Presidio, Gentry Venture Partners, Northgate Capital, Alexandria Real Estate Equities, and Syngenta Ventures.  Additional terms were not disclosed.

“The financing will enable us to continue the development and commercialization of our proprietary INzym platform, which will allow our partners to produce non-food biomass with properties customized to enhance specific chemical processes, including generation of cellulosic biofuels and other related products, within existing infrastructure,” said Mark Wong, CEO of Agrivida.

Earlier this year, Agrivida launched its first significant field production of INzyme materials in U.S. Department of Agriculture-regulated trials. Materials from these trials will be used in larger-scale agricultural and industrial processing trials, to refine both field performance and processing characteristics of Agrivida-modified feedstocks.